KATHRYN MCDONNELL: Open Payments
NPI 1689193518 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$460 in 13 payments from 8 companies in 2025. Trend: 2023 $18 · 2024 $465 · 2025 $460
Food & beverage: $460
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Celgene Corporation | 2 | $46 |
| Janssen Biotech, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 1 | $35 |
| Eisai Inc. | 1 | $34 |
| SpringWorks Therapeutics, Inc. | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $29 |
Products named: VENCLEXTA, ICLUSIG, REBLOZYL, Xtandi, Lenvima, OGSIVEO, Vanflyta, ERLEADA.
Industry payments across IL — which companies pay providers there.
